CC
AVTX icon

Commodore Capital’s Avalo Therapeutics AVTX Stock Holding History

Commodore Capital’s Portfolio AVTX Stock Details AVTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$18.8M Buy
1,018,319
+535,319
+111% +$8.46M 1.12% 22
2026
Q1 		$7.21M Hold
483,000
– – 0.42% 33
2025
Q4 		$8.77M Hold
483,000
– – 0.58% 30
2025
Q3 		$6.14M Hold
483,000
– – 0.3% 35
2025
Q2 		$2.41M Hold
483,000
– – 0.17% 33
2025
Q1 		$3.87M Hold
483,000
– – 0.29% 31
2024
Q4 		$3.59M Hold
483,000
– – 0.26% 29
2024
Q3 		$4.59M Buy
483,000
+443,000
+1,108% +$4.57M 0.29% 36
2024
Q2 		$499K Buy
+40,000
New +$519K 0.03% 35

Other funds holding AVTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
CP
Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Commodore Capital's AVTX Position: Q2 2026 in Review

Commodore Capital increased its Avalo Therapeutics (AVTX) stake by 111% in Q2 2026, buying an estimated $8.46M and bringing the position to 1,018,319 shares worth $18.8M. The position accounts for 1.12% of the portfolio, ranked #22.

Commodore Capital first reported a position in AVTX in Q2 2024 and has held it in 9 quarters since. 126 funds tracked by Wall St. Rank hold AVTX as of Q2 2026.

  • Commodore Capital held 1,018,319 shares of Avalo Therapeutics worth $18.8M as of Q2 2026.
  • Commodore Capital bought 535,319 Avalo Therapeutics shares in Q2 2026, an estimated $8.46M.
  • Avalo Therapeutics made up 1.12% of Commodore Capital's portfolio in Q2 2026, its #22 holding.
  • Commodore Capital first reported a position in Avalo Therapeutics in Q2 2024 and has held it in 9 quarters since.
  • 126 funds tracked by Wall St. Rank held Avalo Therapeutics as of Q2 2026.

Based on Commodore Capital's 13F filing for Q2 2026, filed 14 Aug 2026.